GWM Advisors LLC raised its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.6% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,183 shares of the biopharmaceutical company’s stock after acquiring an additional 491 shares during the period. GWM Advisors LLC’s holdings in Gilead Sciences were worth $958,000 as of its most recent SEC filing.
Other hedge funds have also recently added to or reduced their stakes in the company. Creative Financial Designs Inc. ADV boosted its holdings in Gilead Sciences by 55.9% during the first quarter. Creative Financial Designs Inc. ADV now owns 460 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 165 shares during the period. Trustcore Financial Services LLC acquired a new position in shares of Gilead Sciences during the first quarter valued at about $34,000. Weaver Consulting Group acquired a new position in shares of Gilead Sciences during the first quarter valued at about $34,000. Legacy Advisors LLC acquired a new position in shares of Gilead Sciences during the second quarter valued at about $37,000. Finally, Evolution Wealth Advisors LLC acquired a new position in shares of Gilead Sciences during the second quarter valued at about $46,000. Institutional investors own 78.78% of the company’s stock.
A number of research analysts have recently commented on GILD shares. Maxim Group set a $84.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Wednesday, July 31st. Evercore ISI reaffirmed a “buy” rating on shares of Gilead Sciences in a research report on Friday, May 17th. Raymond James upped their price objective on shares of Gilead Sciences from $83.00 to $86.00 and gave the company a “strong-buy” rating in a research report on Wednesday, July 31st. Royal Bank of Canada raised shares of Gilead Sciences from an “outperform” rating to a “top pick” rating and set a $91.00 price objective for the company in a research report on Monday, July 29th. Finally, Cantor Fitzgerald set a $88.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Monday, July 15th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have issued a buy rating and two have assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $82.29.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.68 by $0.14. Gilead Sciences had a net margin of 26.64% and a return on equity of 37.12%. The firm had revenue of $5.69 billion during the quarter, compared to analyst estimates of $5.54 billion. During the same quarter in the prior year, the business posted $1.91 earnings per share. The company’s quarterly revenue was down 2.8% compared to the same quarter last year. On average, research analysts expect that Gilead Sciences, Inc. will post 6.65 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, September 27th. Investors of record on Friday, September 13th will be given a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 3.92%. The ex-dividend date is Thursday, September 12th. Gilead Sciences’s dividend payout ratio (DPR) is presently 40.98%.
In other news, EVP Brett A. Pletcher sold 5,816 shares of the firm’s stock in a transaction that occurred on Tuesday, June 18th. The shares were sold at an average price of $68.75, for a total transaction of $399,850.00. Following the completion of the sale, the executive vice president now owns 27,198 shares of the company’s stock, valued at $1,869,862.50. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Brett A. Pletcher sold 608 shares of the firm’s stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $64.35, for a total transaction of $39,124.80. Following the sale, the executive vice president now directly owns 27,198 shares of the company’s stock, valued at approximately $1,750,191.30. The disclosure for this sale can be found here. Insiders sold 13,624 shares of company stock valued at $907,479 in the last three months. Company insiders own 0.20% of the company’s stock.
Gilead Sciences Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Featured Story: What are municipal bonds?
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.